Anixa Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ANIX | HURA | VRXA | XLO | ACTI.ST | CHRS | |
|---|---|---|---|---|---|---|
| Market cap | 114.03M | 109.61M | 134.34M | 57.31M | 101.49M | 131.36M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -10.6 | -2.8 | — | -15.0 | — | -1.3 |
| Price/book | 7.8 | 6.0 | -0.7 | 0.8 | 2.7 | 2.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −24.82% | −33.80% | −90.96% | −23.93% | −34.67% | −48.50% |
| Today | +7.36% | +3.93% | −4.04% | +0.35% | +4.62% | +5.54% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ANIX news ›Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026
Nov 04, 2026, 08:35 ET Dr. Robert Wenham, principal investigator of Anixa's Phase 1 clinical trial at Moffitt Cancer Center, to present on December 14 in London Dr. Wenham's presentation, titled "Phase 1 clinical trial of autologous…
Analysts’ Top Healthcare Picks: Anixa Biosciences (ANIX), Lexicon Pharmaceuticals (LXRX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Anixa Biosciences (ANIX) and Lexicon Pharmaceuticals (LXRX) with bullish sentiments. In a report released today, Yi Chen from H.C. Wainwright…
Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial
First patient in fifth cohort exhibiting stable disease 90 days after treatment. Multiple patients surviving more than one year, including one beyond two years, with no dose-limit ... First patient in fifth cohort exhibiting stable disease…
Protalix BioTherapeutics (NYSE:PLX) vs. Anixa Biosciences (NASDAQ:ANIX) Head to Head Survey
Posted by Sarita Garza on Oct 25th, 2026 Anixa Biosciences (NASDAQ:ANIX – Get Free Report) and Protalix BioTherapeutics (NYSE:PLX – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare…
Anixa Biosciences Inc (NASDAQ:ANIX) Stock Has Consensus Target Price of $8.00
Posted by Danessa Lincoln on Oct 22nd, 2026 Read Our Latest Stock Report on ANIX Shares of ANIX stock opened at $2.71 on Thursday. The company has a market capitalization of $94.20 million, a price-to-earnings ratio of -8.47 and a beta of…
Contrasting Immatics (NASDAQ:IMTX) & Anixa Biosciences (NASDAQ:ANIX)
Immatics (NASDAQ:IMTX – Get Free Report) and Anixa Biosciences (NASDAQ:ANIX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their…
Join Anixa Biosciences’ Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine
Management to discuss CAR-T clinical progress, completed Phase 1 breast cancer vaccine trial, planned Phase 2 development, and upcoming milestones ORLANDO, FL / ACCESS Newswire / October 13, 2026 / RedChip Companies will host an investor…
Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
Oct 13, 2026, 08:40 ET Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference Dr. Conejo-Garcia's presentation is titled "Closing in: Cracking Ovarian Cancer's Resistance to Immunotherapy." He…
Anixa's Dr. Conejo-Garcia to present on ovarian cancer immunotherapy at Nov conference
Anixa Biosciences announced that Dr. Jose Conejo-Garcia, inventor of their CAR-T therapy for ovarian cancer, will keynote at the 2026 Ovarian Cancer Midwest Focus Conference. His presentation will focus on overcoming ovarian cancer's…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com2
- defenseworld.net1
- markets.businessinsider.com1
- usatoday.com1
- voiceofalexandria.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.